A Phase 2b, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine, MTBVAC, Against TB Disease in Interferon Gamma Release Assay Positive Adolescents and Adults Aged 14-45 Years, Living in a TB Endemic Region.
Latest Information Update: 25 Mar 2025
At a glance
- Drugs MTBVAC (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- 24 Mar 2025 According to Bharat Biotech media release, The Phase2b efficacy study will be carried out by IAVI and will be funded by BMGF and Open Philanthropy
- 26 Feb 2024 New trial record